Evaluating Liraglutide in Alzheimer's Disease (ELAD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by Imperial College London
Sponsor:
Collaborators:
King's College Hospital NHS Trust
University of Oxford
University of Southampton
Avon and Wiltshire Mental Health Partnership NHS Trust
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT01843075
First received: April 24, 2013
Last updated: March 25, 2014
Last verified: March 2013

April 24, 2013
March 25, 2014
January 2014
January 2017   (final data collection date for primary outcome measure)
The change in cerebral glucose metabolic rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]
The change in cerebral glucose metabolic rate from baseline to follow up (12 months) in the treatment group compared with the placebo group.
Same as current
Complete list of historical versions of study NCT01843075 on ClinicalTrials.gov Archive Site
  • The change in z-scores for the ADAS Exec, MRI changes, microglial activation, and CSF markers [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • The incidence and severity of treatment emergent adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The incidence and severity of treatment emergent adverse events or clinically important changes in safety assessments over 12 months.
Same as current
Not Provided
Not Provided
 
Evaluating Liraglutide in Alzheimer's Disease
Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)

This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). The investigators aim to recruit patients with mild Alzheimer's dementia as defined by the National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) Criteria for Probable Alzheimer's Dementia or meeting Dubois criteria for early AD, with Mini Mental State Evaluation score of at least 22 out of a maximum of 30 and a CDR Global score of 0.5 or 1.

Patients will be randomised on a 1:1 ratio to receive liraglutide or identical matching placebo.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: Liraglutide
    Other Name: Victoza
  • Drug: Placebo
  • Experimental: Liraglutide
    Daily administration of 1.8 mg liraglutide by subcutaneous injection
    Intervention: Drug: Liraglutide
  • Placebo Comparator: Placebo
    Daily administration of matched placebo by subcutaneous injection
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
206
January 2017
January 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Capable of giving and capacity to give informed consent. (Advanced directive will be taken from all patients regarding whether they would like to continue in the study in case they lose their capacity during the study. Carers will be actively involved in the consent process at the beginning of the study)
  2. A carer who can act as a reliable study partner
  3. Diagnosis of Probable Alzheimer's disease according to Dubois criteria (Dubois, Feldman et al. 2007) or National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
  4. Age from 50 to 85 years, inclusive
  5. Mini-Mental State Examination (MMSE) score of ≥22
  6. Rosen Modified Hachinski Ischemic score ≤4
  7. On stable medication for 3 months; on or off cholinesterase inhibitors
  8. Fluency in English and evidence of adequate premorbid intellectual functioning
  9. Likely to be able to participate in all scheduled evaluations and complete all required tests

Exclusion Criteria:

  1. Diabetes
  2. Any contraindications to the use of liraglutide as per the Summary of Product Characteristics. (hepatic impairment, renal impairment with CKD stage 3 and above, inflammatory bowel disease)
  3. Significant neurological disease other than AD that may affect cognition
  4. MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with regard to their dementia
  5. Currently taking or having taken memantine on the 30 days prior to screening
  6. Current presence of a clinically significant major psychiatric disorder (e.g., Major Depressive Disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
  7. Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study
  8. History of seizures, excluding febrile seizures in childhood
  9. Treatment with immunosuppressive medications (e.g. systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years
  10. Myocardial infarction within the last 1 year
  11. History of cancer within the last 5 years
  12. Other clinically significant abnormality on physical, neurological or laboratory examination that could compromise the study or be detrimental to the patient
  13. History of alcohol or drug dependence or abuse within the last 2 years
  14. Current use of anticonvulsant, anti-Parkinson's, anticoagulant (excluding the use of aspirin 325 mg/day or less) or narcotic medications
  15. Use of experimental medications for AD or any other investigational medication or device within 60 days. Patients who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial
  16. Women of childbearing potential. Women who could become pregnant will be required to use adequate contraception throughout the trial
  17. Patients with a personal or family history of medullary thyroid carcinoma (MTC) and patients with multiple endocrine neoplasia type 2 (MEN2)
Both
50 Years to 85 Years
No
Contact: Paul Edison, MBBS PhD FRCPI +44 (0) 2033133275 paul.edison@imperial.ac.uk
Contact: Vicky Tsipouri, PhD v.tsipouri@imperial.ac.uk
United Kingdom
 
NCT01843075
U1111-1131-9252
Not Provided
Imperial College London
Imperial College London
  • King's College Hospital NHS Trust
  • University of Oxford
  • University of Southampton
  • Avon and Wiltshire Mental Health Partnership NHS Trust
Principal Investigator: Paul Edison, MBBS, PhD, FRCPI Imperial College London
Imperial College London
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP